India, May 7 -- PharmEasy-owned diagnostics major Thyrocare Technologies reported a sharp rise in its bottom line in Q4 FY26, with consolidated net profit surging 128% to Rs.48.7 Cr from Rs.21.3 Cr in the corresponding quarter last year.

On a sequential basis, profit rose 22% from Rs.39.9 Cr, driven by strong operating leverage and volume growth.

Revenue from operations grew 20% to Rs.224 Cr during the quarter under review from Rs.187.2 Cr in Q4 FY25. Sequentially, revenue rose about 5% from Rs.213.3 Cr.

Growth was led by continued momentum in its core pathology segment, which expanded 21% YoY, with franchise revenue up 21% and partnership revenue rising 23%.

Total expenses increased in line with business expansion, growing 13.9% YoY ...